311P PFS2 and 3 after first-line CDK4/6i in HR+/HER2- metastatic breast cancer patients based on PAM50 intrinsic subtype and treatment strategies within the SOLTI-1801 CDK-PREDICT studyP. Tolosa Ortega, E.M. Ciruelos, S. Servitja Tormo et al.|ESMO Open|2025Cited by 0
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Isabel García-Fructuoso et al.|Breast Cancer Research and Treatment|2026Cited by 0